News >

Plasma-Based TMB May Predict Pembrolizumab Response in NSCLC

Ellie Leick
Published: Tuesday, Mar 24, 2020

Charu Aggarwal, MD, MPH,the Leslye Heisler Assistant Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania's Perelman School of Medicine

Charu Aggarwal, MD, MPH

Plasma-based tumor mutational burden (TMB) has potential as a predictive biomarker for responses to immunotherapy or immunotherapy combinations in patients with non–small cell lung cancer (NSCLC), explained Charu Aggarwal, MD, MPH.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication